Chemistry42: An AI-based platform for de novo molecular design
Not on the map. Why?
Abstract (arXiv)
Chemistry42 is a software platform for de novo small molecule design that integrates Artificial Intelligence (AI) techniques with computational and medicinal chemistry methods. Chemistry42 is unique in its ability to generate novel molecular structures with predefined properties validated through in vitro and in vivo studies. Chemistry42 is a core component of Insilico Medicine Pharma.ai drug discovery suite that also includes target discovery and multi-omics data analysis (PandaOmics) and clinical trial outcomes predictions (InClinico).
Key facts. Cited by 1 paper in the map (data through 14 Oct 2026). Builds on 1 of its 25 references that are in the map. First posted on arXiv 22 Jan 2021.
Builds on
1 of 25 references.
References · 1
Built on by
Citing papers per year: 2022: 1.
1 paper.